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Abstract 
Clinical experiences often document, that a successful tumor control requires high doses of 
drug applications. It is widely believed that unavoidable adverse reactions could be minimized 
by using gene-therapeutic strategies protecting the tumor-surrounding healthy tissue as well 
as the bone-marrow. One new approach in this direction is the use of “Targeted Therapies” 
r e a l i z i n g   a   s e l e c t i v e   d r u g   t a r g e t i n g   t o   g a i n   e f f e c t u a l   a m o u n t s   a t   t h e   t a r g e t   s i t e ,   e v e n   w i t h  
drastically reduced application doses. MCF-7 breast cancer cells expressing the αvβ3 [al-
p h a ( v ) b e t a ( 3 ) ]   i n t e g r i n   r e c e p t o r   a r e   c o n s i d e r e d   a s   a p p r o p r i a t e   c a n d i d a t e s   f o r   s u c h   a   t a r g e t e d  
therapy. The modularly composed BioShuttle carrier consisting of different units designed to 
facilitate the passage across the cell membranes and for subcellular addressing of diagnostic 
and/or therapeutic molecules could be considered as an eligible delivery platform. Here we 
used the cyclic RGD-B i o S h u t t l e   a s   a   c a r r i e r   f o r   t e m o z o l o m i d e   ( T M Z )   a t   t h e   αvβ3 integrin 
receptor realizing local TMZ concentrations sufficient for cell killing. The IC50 values are 12 
µMol/L in the case of cRGD-BioShuttle-TMZ and 100 µMol/L for underivatized TMZ, which 
confirms the advantage of TMZ reformulation to realize local concentrations sufficient for cell 
killing. 
Our paper focuses on the design, synthesis and application of the cRGD-BioShuttle conjugate 
composed of the cyclic RGD, a αvβ3 integrin-ligand, ligated to the cytotoxic drug TMZ. The 
ligation was carried out by the Diels Alder Reaction with inverse electron demand (DARinv). 
Key  words:  Click-Chemistry,  Cycloaddition,  BioShuttle,  Ligation  chemistry,  Linker  Systems, 
Adaptor Systems, inverse Diels Alder Reaction, RGD, Tetrazines, targeted Therapy, Temozolomide 
Introduction 
B r e a s t   c a n c e r   i s   o n e   o f   t h e   m o s t   c o m m o n   m a l i g-
nancies  affecting  women  in  developed  countries.[1] 
A p p r o x i m a t e l y   t h r e e   o u t   o f   f o u r   w o m e n   w i t h   b r e a s t  
c a n c e r   d e v e l o p   m e t a s t a s e s   i n   b o n e   w h i c h ,   i n   t u r n ,  
diminish the quality of life.[2] An optimal treatment 
concept for patients needs different therapy modali-
ties and methods with an optimum in efficiency and 
the greatest possible protection. Attention should be Int. J. Med. Sci. 2010, 7 
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laid on an individual and not just standardized plan 
of treatment for every single patient and all available 
therapy options should be used, such as immunothe-
rapy, surgery or chemotherapy  sensibly  using  cytos-
tatic active agents with acceptable adverse reactions. 
I t   i s   r e m a r k a b l e   h o w   d a t e d   m e d i c a l   t r e a t m e n t   m e-
thods are persistently continued [reported during the 
“International Brain Tumor Research Conference 2010 
(http://www.kgu.de/index.php?id=4290)]. 
T o x i c   s i d e   e f f e c t s   a r e   d o c u m e n t e d   f o r   T M Z   a s  
adverse reactions in the bone-marrow. Moreover, it is 
known from clinical experience, that even higher ap-
p l i c a t i o n   d o s e s   a r e   n e c e s s a r y   f o r   s u c c e s s f u l   t u m o r  
control. This approach seems obsolete now,  because 
’ T a r g e t e d   T h e r a p y ’   h a s   r e a c h e d   t h e   f o c u s   o f   s c i e n t i f i c  
interest in order to minimize such unavoidable drastic 
side  effects.  Strategies  were  discussed  during  the 
aforementioned meeting to protect the bone-marrow, 
e.g.  with  gene-therapeutic  methods.  Another  inter-
esting  field  is  the  regional  chemotherapy  in  which 
cytostatic drugs are being locally applied to certain 
body  regions.  The  topical  application  increases  the 
a m o u n t   o f   a c t i v e   s u b s t a n c e s   i n   t h e   t u m o r   a n d   i m-
proves efficiency, while lowering the side effect rate at 
the same time.  
However, many cell immanent obstacles inhibit 
c h e m i c a l   t h e r a p y ,   s u c h   a s   t h e   m u l t i d r u g   r e s i s t a n c e  
(MDR)  mediated  against  cytotoxic  agents  like  TMZ, 
and apoptosis resistance with disruption of the com-
plex  programmed  cell  death  pathway  network.  The 
Janicke group documented apoptosis resistant MCF-7 
breast  cancer  cells  treated  with  ionizing  radiation, 
however especially breast micro-metastases are diffi-
cult to determine and even more difficult to treat ef-
fectively. 
Therefore only a selective targeting of the drug 
c a n   d e l i v e r   a n   e f f e c t u a l   a m o u n t   o f   T M Z   t o   i t s   t a r g e t  
site, even with drastically reduced application doses. 
H o w   t o   p e r f o r m   t h i s   i s   e x e m p l a r i l y   s h o w n   h e r e   b y  
targeting and controlling breast cancer cells. 
Our  considerations  to  overcome  these  resis-
tance-i n d u c i n g   f a c t o r s   l e d   t o   t h e   a p p l i c a t i o n   o f   l i-
gands, which are target-specific  for  cell-typical sur-
face receptors, as described as follows. 
On these cells the αvβ3 [alpha(v)beta(3)] and αvβ5 
[alpha(v)beta(5)]integrins are heterodimeric cell sur-
face receptors which mediate adhesion between cells 
and the extracellular matrix.[3] The αvβ3 receptor has 
previously  been  implicated  in  a  key  role  of  tumor 
progression,  metastasis  and  osteoclast  bone  resorp-
tion.  [4]  Integrins,  the  corresponding  ligands,  are 
evolutionarily old and have critical roles during de-
velopmental and pathological processes. The antibo-
dies  to  αvβ3  integrin  and  its  antagonists  like 
arg-gly-asp  (RGD)-containing  peptides,  including 
osteopontin, bone sialoprotein, vitronectin and fibri-
nogen are considered as efficient inhibitors which can 
control the tumor progression.[5] 
This αvβ3 integrin receptor is documented as an 
outstanding target in the field of tumor imaging [6-8] 
and is equally important as a chemotherapeutic target 
in the field of targeted therapy.[9] 
Endocytosis-mediated intracellular trafficking of 
ligands via the αvβ3 receptor of MCF-7 cells and the 
αvβ5 integrin receptor into the perinuclear region of 
HeLa cells is documented, which lack the functional 
αvβ3  receptor.[10]  Interestingely  HeLa  cells,  which 
express the αvβ3 integrin receptor at low level, possess 
lower invasive potential than MCF-7   c e l l s .   I n   o u r   e x-
periments we used MCF-7   h u m a n   b r e a s t   c a n c e r   c e l l s  
a n d   H e L a   c e r v i x   c a n c e r   c e l l s   t o   i n v e s t i g a t e   t h e   n e w  
cRGD-BioShuttle as a delivery platform for targeting 
w i t h   T M Z   i n   o r d e r   t o   r e a l i z e   h i g h   l o c a l   T M Z   c o n c e n-
trations  at  the  MCF-7 and HeLa cell’s surfaces and, 
after uptake into the cells sufficient for cell killing.  
T h i s   p a p e r   i n t e n d s   t o   s u m m a r i z e   t h e   m a j o r   e f-
forts  reached  thus  far  and  focuses  on  the  design, 
synthesis  and  application  of  the 
cRGD-BioShuttle-T M Z   c o n j u g a t e .   T h e   w h o l e   m o l e-
cule was synthesized via Diels Alder Reaction with 
i n v e r s e   e l e c t r o n   d e m a n d .   I t   i s   c o m p o s e d   o f   t h e   c y c l i c  
RGD-containing the αvβ3 and αvβ5 integrin antagonist 
cRGD.  
Cell culture 
The  estrogen  sensitive  MCF-7  adenocarcinoma 
breast cancer and HeLa cervix cancer cells (dkfz, tu-
morbank)  were maintained at 37°C in a 5% CO2 at-
mosphere  in  RPMI  cell  medium  (Gibco,  Germany) 
supplemented  with  5%  fetal  calf  serum  (Biochrome, 
Germany). The cells were split twice a week.  
Chemical Procedures 
Synthesis of the RGD-BioShuttle 
Derivatization of temozolomide 
N-(2-Aminopropyl)-4-(6-(pyrimidine-2-yl)-1,2,4,5-tetrazine-3-yl)be
nzamide 4 
4-(6-(Pyrimidine-2-yl)-1,4-dihydro-1,2,4,5-tetrazi
ne-3-yl)benzoic  acid  (3)  was  prepared  from 
2-cyanopyrimidine  1 and  4-cyano-benzoic  acid  2 by 
reaction with hydrazine and then oxidized with so-
dium nitrite to the tetrazine derivative 4 according to 
the following procedure [11]. The tetrazine derivative 
was converted with thionyl chloride under standard 
conditions to the chloride 5.   T o   t h i s   s u s p e n s i o n   o f   t h e  
acid chloride (2 mmol) in 20 ml CH2Cl 2 a solution of Int. J. Med. Sci. 2010, 7 
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N-Boc-1,3-diaminopropane  (2  mmol)  and  TEA  (2 
mmol)  in  10  ml  CH2Cl 2 was slowly added at 0-5°C. 
The  resulting  solution  was  deeply  coloured  and 
maintained  for  4  h  at  room  temperature.  Then  the 
organic phase was w a s h e d   w i t h   w a t e r ,   f o l l o w e d   b y  
1N HCl and again water. The organic layer was dried 
over  Na2SO4  and  evaporated.  The  resulting  residue 
w a s   c h r o m a t o g r a p h e d   o n   s i l i c a   g e l   b y   e l u t i o n   w i t h  
chloroform/ethanol (9:1) and further purified by re-
crystallization  from  ac e t o n e .   Y i e l d :   5 0   t o   7 0   %   d e-
p e n d i n g   o n   t h e   q u a l i t y   o f   t h e   c a r b o x y l i c   a c i d .   E S I   M S :  
m/z  437.2  [M]+.   T h e   B o c -protected  derivative  was 
t r e a t e d   w i t h   T F A   ( 5   m l )   f o r   3 0   m i n   a t   r o o m   t e m p e r a-
t u r e   a n d   i s o l a t e d   b y   e v a p o r a t i o n   t o   a   s o l i d   r e s i d u e   ( 6) 
(ESI: m/z 337.2 [M]+ (as shown in Figure A). 
 
 
 
Figure A  shows  the  mass  of  the 
N-(2-Aminopropyl)-4-(6-(pyrimidine-2-yl)-1,2,4,5-tetrazine
-3-yl)benzamide (6 in scheme 1/Figure S1), as discussed by 
Wiessler [12]. 
 
 
3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carb
oxylic acid chloride 7 
3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,
5]tetrazine-8-c a r b o x y l i c   a c i d   w a s   c o n v e r t e d   t o   t h e  
corresponding  chloride  7  as  documented  by  Ar-
rowsmith [13].   T h e   a c i d   ( 2   m m o l )   w a s   r e f l u x e d   w i t h  
thionyl chloride (10 ml) until the acid was completely 
d i s s o l v e d .   T h e   e x c e s s   o f   t h i o n y l   c h l o r i d e   w a s   e v a p o-
rated  under  vacuum   a n d   t h e   r e s u l t i n g   s o l i d   w a s  
stored over NaOH. 
3-Methyl-4-oxo-N-(3-(4-(6-(pyrimidine-2-yl)-1,2,4,5-tetrazine-3-yl)
benzamido)propyl)-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine- 
8-carboxamide (TMZ-tetrazine diene) 9 
Compound 8 (0.5 mmol) and the chloride 7 (0.5 
mmol) were dissolved in 5 ml chloroform and 5 ml 
T E A   a t   0 -5   ° C .   A f t e r   4   h   a t   r o o m   t e m p e r a t u r e ,   t h e   s o-
lution was washed with water, 1 N HCl and again 
with water. The organic layer was dried over Na2SO4 
and evaporated. The r e s i d u e   w a s   p u r i f i e d   b y   c h r o-
matography  (silica  gel)  with  chloroform/ethanol 
(9.5/0.5). Yield: 68%: ESI: m/z 536.3 [M+Na]+. (Figure 
B) 
 
 
 
 
Figure B  shows  the  mass  of 
3-methyl-4-oxo-N-(3-(4-(6-(pyrimidine-2-yl)-1,2,4,5-tetrazi
ne-3-yl)benzamido)propyl)-3,4-dihydroimidazo[5,1-d][1,2,3
,5]tetrazine-8-carboxamide  {TMZ-tetrazine  diene  (9  in 
scheme 1/Figure S1)} [12]. 
 
 
 
Derivatizations of the cRGD 
Synthesis of the Reppe anhydride 12 
The  tetracyclo-[5.4.21,7.02,6.08,11]3,5-dioxo-4-aza- 
9,12-tridecadiene (Reppe-anhydride) 12 was prepared 
f r o m   4 2   m g   o f   ( 1 Z , 3 Z , 5 Z , 7 Z ) -cycloocta-1,3,5,7-tetraene 
10 and 44 mg maleic anhydride 11 in chloroform as 
documented by Reppe [14].  
 Int. J. Med. Sci. 2010, 7 
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Figure S1 (Scheme 1)  the  nitriles  1  and  2  react  with  hydrazine  to  the  4-(6-(pyrimidine-2-yl)-1,4-dihydro- 
1,2,4,5-tetrazine-3-yl)benzoic acid 3. Oxidation to 4 and reaction with thionyl chloride result in the corresponding acide 
c h l o r i d e   5   w h i c h   r e a c t s   w i t h   N-Boc-1,3-diaminopropane to the product 6. Boc-deprotection and subsequent reaction with 
3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylic  acid  chloride  7  result  in  the  product 
3-Methyl-4-oxo-N-(3-(4-(6-(pyrimidine-2-yl)-1,2,4,5-tetrazin-3-yl)benzamido)propyl)-3,4-dihydroimidazo[5,1-d][1,2,3,5]tet
razine-8-carboxamide (TMZ-tetrazine diene) 9. 
 
Figure S2 (Scheme 2) illustrates the chemical reaction of (1Z,3Z,5Z,7Z)-cycloocta-1,3,5,7-tetraene 10 and 44 mg maleic 
anhydride 11 which produces the tetracyclo-[5.4.2
1,7.0
2,6.0
8,11]-3,5-dioxo-4-aza-9,12-tridecadiene 14 (NMH data of 12 are 
shown in the Figure C.  Int. J. Med. Sci. 2010, 7 
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Figure C  shows  the 
1H-NMR-spectrum  of  the  Reppe 
A n h y d r i d e   { T c T   =   ( Tetracyclo-[5.4.2
1,7.O
2,6.O
8,11] 
3,5-dioxo-4-aza-9,12-tridecadiene in CDCl3}. The structure 
describes the shift calculation for protons of the compound 
with ChemDraw Ultra 2004. (Numbers indicate the pre-
dicted shift of the signals in ppm, as discussed by Wiessler 
[12].  
Synthesis of the dienophile cRGD-Lys(Tct) (14) 
3 0   µ m o l   c R G D   p e p t i d e   ( 1 8   m g )   13 and 40 µm o l   ( 8  
mg)  tetracyclo-[5.4.21,7.02,6.08,11]3,5-dioxo-4-aza-9,12- 
tridecadiene  12  were  dissolved  in  pyridine  over  5 
hours at 70° - 80°C. Yield: 6 mg 14. Empirical formula 
C39H49N9O9; exact Mass: 787.37 Mol. Wt.: 787.86 
m/e:  787,37  (100,0%),  788,37  (43,1%),  789,37 
(12,3%), 788,36 (3,3%), 790,38 (1,2%), 790,37 (1,1%) C, 
59.45; H, 6.27; N, 16.00; O, 18.28 m/e peak at 788.5 for 
the product. 
L i g a t i o n   o f   t h e   c R G D -L y s ( T c t )   w i t h   t h e   T M Z -tetrazine 9 
Equimolar  amounts  of  the  TMZ-tetrazine  con-
jugate 9 (1.03 mg; 2 µmol) and cRGD-Lys(Tct) 14 (7.3 
mg, 2 µmol) were dissolved in aqueous solution and 
s t o r e d   a t   r o o m   t e m p e r a t u r e   f o r   2 4   h .   T h e   D A R inv re-
action occurs at room temperature and was completed 
a f t e r   t h e   c o l o u r   c h a n g e d   f r o m   m agenta to yellow. The 
product  15 (cRGD-BioShuttle-TMZ)   w a s   i s o l a t e d   b y  
lyophilization; yield: 98 %); MS ESI: m/e 1634.8; cal-
culated C81H91N19O15S2 1633.6. 
 
 
Figure S3 (Scheme 3) shows the DARinv reaction of the diaryl-tetrazine harbouring TMZ 9 with cRGD functionalized with 
the Reppe Anhydride 14 to the product 15 (cRGD-BioShuttle-TMZ).  Int. J. Med. Sci. 2010, 7 
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Synthesis of the cRGD-dansyl 
For investigations of the cellular localization of 
t h e   c R G D   w e   f u n c t i o n a l i z e d   t h e   c R G D   w i t h   t h e   f l u o-
rescent  dye  5-(dimethylamino)-naphthalene-1- 
sulfonyl, (dansyl, as shown in scheme 4/Figure S4).  
 
Figure S4 (Scheme 4) shows  the  DARinv  reaction  of  the  diaryl-tetrazine  harbouring  the  5-(dimethylamino)- 
naphthalene-1-sulfonyl  dye  16  with  cRGD  functionalized  with  the  Reppe  Anhydride  14  to  the  product  17 
(cRGD-BioShuttle-dansyl). 
 
Synthesis of the cRGD-dansyl 17 
2   µ m o l   ( 1 . 7 5   m g )   o f   p u r i f i e d   14 reacts over 24 
hours with 2.5 µmol (2.18 mg) 16 dissolved in DMSO 
a t   r o o m   t e m p e r a t u r e   t o   t h e   p r o d u c t   17. The reaction 
mixture  was  concentrated.  After  HPLC  purification 
t h e   e s t i m a t i o n s   o f   i d e n t i t y   s h o w   i n   p o s i t i o n   1 6 3 4 ,  
Mode m/e. 
Exact Mass: 1633.64; Mol. Wt.: 1634.84 
m/e:  1633.64  (100.0%),  1634.64  (97.8%),  1635.65 
(39.3%),  1636.65  (14,2%),  1636.64  (11.9%),  1635.64 
(10.8%), 1635.63 (9.4%), 1637.65 (4,7%), 1637.64 (4,2%), 
1638.64 (1.6%) 
C, 59.51; H, 5.61; N, 16.28; O, 14.68; S, 3.92 
Chemotherapy treatment of MCF-7 breast can-
cer and HeLa cervix cancer cells 
Pure  temozolomide  (TMZ)  [Sigma-Aldrich, 
G e r m a n y   ( C a t .   N o .   7 6 8 9 9 ) ]   w a s   s u b d i v i d e d   i n t o   two 
p a r t s   f o r   s u b s e q u e n t   p r o c e s s i n g .   O n e   p a r t   w a s   k e p t  
underivatized  for  the  following  experiment and the 
second part, after chemical transformation to the cor-
responding acid chloride 7,   w a s   u s e d   f o r   c o u p l i n g   t o  
the  cRGD  [Peptides  International,  USA  (Cat.  No. 
PCI-3661-PI)] transporter molecule.  
TMZ  and  cRGD-BioShuttle-TMZ  15  were  both 
dissolved  in  10  %  aqueous  solution  of  acetonitrile 
(Sigma-A l d r i c h ,   G e r m a n y ) .   C o n t r o l   s t u d i e s   w i t h   a c e-
tonitrile  were  performed  to  exclude  potential  toxic 
effects of this solvent.  
MCF-7   a n d   H e L a   c e l l s   w e r e   g r o w n   a s   s u b c o n-
f l u e n t   m o n o l a y e r s   i n   R P M I   (control)  and  in  RPMI 
containing  appropriate  amounts  of  TMZ  and  the 
cRGD-BioShuttle-TMZ  15  ( 5 0   µ M )   a n d   t h e i r   b e h a v-
iour was analyzed for up to 72 hours.  
Morphological evaluation 
Microscopical studies of the human cancer cells 
w e r e   c a r r i e d   o u t   w i t h   a n   Olympus inverted micro-
scope under phase contrast conditions. The magnifi-
c a t i o n   w a s   2 0 0 f o l d .   T h e   c e l l s   w e r e   o b s e r v e d   d u r i n g  
their culture in medium and during  treatment  with 
the different drugs. Int. J. Med. Sci. 2010, 7 
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Cellular localization of the 
cRGD-BioShuttle-dansyl 
In order to reconfirm our data documenting an 
endocytotic  internalization  of  the  cRGD  into  the  cy-
toplasm of αvβ3 and αvβ5 integrin expressing cells we 
used the confocal laser scanning microscope (CLSM) 
of the Microscopy Core Facility of the German Cancer 
Research Cen t e r   f o r   q u a l i f i e d   v e r i f i c a t i o n   o f   t h e   d a t a .  
T h e   p i c t u r e s   w e r e   t a k e n   w i t h   a   L e i c a   c o n f o c a l   m i c r o-
s c o p e   T C S   S P 5   I I   ( e x c i t a t i o n   a t   4 0 5   n m ,   e m i s s i o n   a t  
420-5 6 0   n m )   a n d   e x a m i n e d   w i t h   t h e   L e i c a  
LAS-Software.  
24 hours before CLSM measurements both cell 
lines, the HeLa and the MCF-7 cells (5×105), were cul-
tivated  in  8-well  cell  culture  plates  (Lab-Tek)  and 
treated  with  the  cRGD-BioShuttle-dansyl  (12.5  µM) 
17.  
Cytotoxic Measurements 
For  the  toxicological  characterization  of  the 
cRGD-BioShuttle-TMZ  conjugate  15  as  well  as  the 
c R G D   a n d   t h e   T M Z   a l o n e  as controls were added to 
the  MCF-7 cell line’s medium. The substances  were 
incubated in a dilution series ranging from 12.5, via 
25, 50, to 100 µM final concentrations up to 72 hours. 
The IC50 values were determined and also converted 
to the pIC50 scale (-log IC50) (Table 1).  
Multiparametric Flow Cytometry Analysis 
Cell size and granularity 
T h e   u s e   o f   t h e   f l o w   c y t o m e t r y   p a r a m e t e r s   f o r-
ward (FSC) and sideward (SSC) scatter of the cells 
give an indication on drug effects through the relative 
cell  size  and  structural  effects  such  as  granularity. 
Both parameters suffice for a rough cell characteriza-
tion.  The  cells  (treated  with  the  components  as  de-
scribed  above  and  an  untreated  control)  could  be 
clearly distinguished as shown in the Figure 5.  
 
Results 
This manuscript details the synthetic steps of our 
n e w   c R G D -BioShuttle-T M Z   a n d   illustrates the cellular 
uptake  of  this  newly  synthesized 
cRGD-BioShuttle-TMZ  in  comparison  to  its  controls 
as outlined in the respective experiments. We exam-
ined MCF-7   a n d   H e L a   c e l l s   s u r f a c e   t a r g e t i n g   o f   t h e s e  
molecules with the cytotoxic drug TMZ as a cargo.  
Light Microscopical Studies 
I n   l i g h t   m i c r o s c o p y   w e   f i r s t   i n v e s t i g a t e d   t h e   c e l l  
killing effect of cRGD-Bioshuttle-TMZ 15 compared to 
underivatized TMZ. We achieved a rapid and high 
local concentration and an accumulation of TMZ on 
the  surface  of  the  targeted  αvβ3  integrin expressing 
MCF-7   c e l l s   b y   u s e   o f   t h e   c R G D -BioShuttle as delivery 
and targeting platform.  
Figure 1 r e v e a l s   t h e   d i f f e r e n t   e f f e c t s   o f   T M Z   a n d  
cRGD-BioShuttle-TMZ on MCF-7 cells tested after 24 
hours and 72 hours of treatment with a final concen-
tration of 50 µM. Whereas the MCF-7 cells exhibit no 
formation of the squamous epithelium (B), the MCF-7 
cells  seem  to  be  unimpressed  by  TMZ  treatment 
(bottom  row  C) and resemble the untreated control 
(top row A) as shown in the microscopic pictures. 
Figure  2  indicates a clear change of the MCF-7 
phenotype  dependent  on  the  concentrations  of 
cRGD-BioShuttle-T M Z   o f   u p   t o   5 0   µ M .   T h e   u n t r e a t e d  
c o n t r o l   c e l l s   a r e   s h o w n   i n   t h e   b o t t o m   r o w   f o r   e a c h  
treatment  regimen.  The  final  concentrations  of  the 
cRGD-BioShuttle-T M Z   a n d   T M Z   w e r e   f r o m   1 2 . 5   µ M ,  
v i a   2 5   µ M   t o   5 0   µ M   a s   i n d i c a t e d   i n   t h e   f i g u r e   2 .   A  
drastic cell killing of the MCF-7   c e l l s   w a s   o b s e r v e d   b y  
the  targeted  approach,  whereas  the  MCF-7  cells 
treated with underivatized temozolomide seemed to 
be  not  affected.  Independent  of  the  final  TMZ  con-
centrations  used,  they  looked  identical  to  the  un-
treated control cells. 
Cellular Localization Studies using Confocal La-
ser Scanning Microscopy – CLSM 
I n   o r d e r   t o   i n v e s t i g a t e   t h e   o p e n   q u e s t i o n   o f   t h e  
cellular localization of the cRGD-BioShuttle-TMZ  we 
ligated a   f l u o r e s c e n c e   d y e   t o   c R G D .   T h i s   “ B i o S h u t t l e ”  
( c y c l o   R G D )   c o n n e c t e d   t o   a   f l u o r e s c e n t   t a g   d a n s y l   ( a s  
shown  in  scheme  4/Figure  S4)   w a s   a p p l i e d   t o   t h e  
c u l t u r e   m e d i a   o f   t h e   αvβ3 and αvβ5 integrin expressing 
MCF-7 and the low ex p r e s s i n g   H e L a   c e l l s .   T h e   c e l l s  
lines clearly show differences in the fluorescence sig-
nal  localizations.  Two  hours  after 
cRGD-BioShuttle-dansyl  application  a  blue  perinu-
clear dansyl fluorescence signal could be observed in 
MCF-7 .   T h e   c e l l   n u c l e u s   d i s p l a y e d   n o   s i g n a l   a t   a l l . The 
HeLa cells show a cells surface located fluorescence 
signal (Figure 3, top row).  
24 hours after cRGD-BioShuttle-dansyl  applica-
tion the fluorescence signal increased in the cytoplasm 
of  MCF-7 and at the surface of HeLa cells,  but  the 
signal  localizations  remained  unaltered.  A  nuclear 
located fluorescence signal was still lacking (as shown 
in Figure 3, second row). The pictures from 48 and 72 
hours after application demonstrate a decreased flu-
orescence signal suggesting  a n   e f f l u x   o f   t h e   d a n s y l  
fluorescence dye out of the MCF-7 cell’s cytoplasm, 
whereas  in  contrast  the  fluorescence  signal  at  the 
HeLa cell’s surface is unchanged (Figure 3, row 3 and 
bottom row).  Int. J. Med. Sci. 2010, 7 
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Cellular localization of the dansyl fluorochrome 
For detailed information about the cellular loca-
l i z a t i o n   o f   t h e   d a n s y l   f l u o r o c h r o m e   8   p i c t u r e s   o f   a  
z-s t a c k   w e r e   v i s u a l i z e d   i n   l a y e r s   b y   C L S M .   I t   i s   d e-
monstrative, that some fluorescence signals are shown 
i n s i d e   o f   t h e   c e l l s ,   b u t   t h e   s i g n a l   i s   not only localized 
at  the  cell’s  surface  but  also  detectable  inside  as 
pointed out in the legend of the figure 4.  
Multiparametric FACS analysis 
T h e   m o r p h o l o g i c a l   p a r a m e t e r s   o f   t h e   F A C S  
a n a l y s i s   s h o w s   a n   u n a l t e r e d   c e l l   s i z e   ( F i g u r e   5 ,  bottom 
row), whereas the granularity (influenc e d   b y   s i z e   a n d  
s t r u c t u r e   o f   t h e   c e l l   n u c l e u s   a n d   b y   t h e   q u a n t i t y   o f  
vesicles) is changed and shows an increased fraction 
o f   m o r e   g r a n u l i z e d   M C F -7  cells  in  all  treatments 
( T M Z ,   c R G D ,   a n d   cRGD-BioShuttle-TMZ) in contrast 
t o   t h e   u n t r e a t e d   M C F -7   c o n t r o l   c e l l s .   A s   d e m o n s t r a t e d  
in figure 5 the granularity of MCF-7 cells is increased 
i n   c e l l s   t r e a t e d   w i t h   T M Z   a n d   c R G D   ( 1 0 0   µ M   r e s p e c-
t i v e l y ) .   T h e   m o s t   c o n s p i c u o u s   g r a n u l a r i t y   w a s   o b-
tained  after  cRGD-BioShuttle-T M Z   i n   t h e   f i n a l   c o n-
c e n t r a t i o n   o f   1 2 . 5   µ M   a s   s h o w n   i n   t h e   b l o t   o f   t h e  figure 
5 (right column, row 1). 
T h e   t r e a t m e n t   o f   T M Z ,   c R G D ,   a n d  
cRGD-BioShuttle-TMZ in the concentrations as men-
tioned  above  shows  no  visible  influence  on  the  cell 
size of MCF-7 cells. 
 
Figure 1  shows m i c r o s c o p i c a l   D I C   s t u d i e s   o f   h u m a n   b r e a s t   c a n c e r   c e l l s   ( M C F -7 ) .   T h e   t o p   r o w   ( A) shows the phenotype 
o f   u n t r e a t e d   M C F -7   c e l l s .   T h e   c e n t e r   r o w   ( B) exhibits MCF-7   c e l l s   a f t e r   2 4   h o u r s   ( l e f t   c o l u m n )   a n d   7 2   h o u r s   ( r i g h t   c o l u m n )  
of treatment with the cRGD-BioShuttle-T M Z   1 5   t a r g e t e d   t o   t h e   M C F -7 cells surface arranged αvβ3 and αvβ5 integrins. 
MCF-7   c e l l s   t r e a t e d   w i t h   T M Z   a l o n e   a r e   s h o w n   i n   t h e   b o t t o m   r o w   ( C) .   T h e   f i n a l   c o n c e n t r a t i o n s   o f   t h e   t e s t e d   T M Z   a n d  
cRGD-Bioshuttle-TMZ were 50 µM. The magnification was 200× with phase contrast. Int. J. Med. Sci. 2010, 7 
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Figure 2  illustrates the concentration dependent change of the phenotype of MCF-7 cells 72 hours after treatment with 
TMZ alone and cRGD-BioShuttle-TMZ. The left column represents the TMZ treatment; the untreated controls are at the 
lower end. The columns on the right side show treatment with the cRGD-BioShuttle-TMZ beginning with 50 µM via 25 µM 
to 12.5 µM. 
 Int. J. Med. Sci. 2010, 7 
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Figure 3  The  figure  shows 
CLSM pictures of breast cancer 
cells MCF-7 (right column) and 
cervix  cancer  cells  HeLa  (left 
column). The lines of the figure 
indicate the measurement time 
points from 2h, 24h, 48h, up to 
72h and suggest a different cel-
lular  localization  of  the 
cRGD-BioShuttle-dansyl  mole-
cule  in  both  investigated  cell 
lines.  Two  hours  after 
cRGD-BioShuttle-dansyl  appli-
cation the molecule seems to be 
arrested on the surface of HeLa 
cells,  whereas  the  dan-
syl-fluorescence  can  be  ob-
served  in  the  cytoplasm  of 
MCF-7 cells. 24 hours later and 
up to 72 hours, the localization 
of  the  fluorescence  signal  was 
unaltered on th e   s u r face of HeLa 
cells. The MCF-7   c e l l s   s h o w   a  
clear fluorescence signal in the 
cytoplasm  except  from  cell 
nuclei which present no signal. 
From  48  to  72  hours  after 
cRGD-BioShuttle-dansyl  appli-
cation the fluorescence signal in 
the  MCF-7’s  cytoplasm  dimi-
nishes  increasingly.  The  final 
concentration  of  the 
cRGD-BioShuttle-dansyl was 50 
µM. Int. J. Med. Sci. 2010, 7 
 
http://www.medsci.org 
336 
 
Figure 4  The gallery represents 8 CLSM pictures of treated HeLa cells in the x, y, and in the z-direction showing layers 
across HeLa cells. The pictures are taken from top to the bottom in a 2 µM distance. In these HeLa cells we were able to 
detect also some material taken up by these cells. Int. J. Med. Sci. 2010, 7 
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Figure 5  the FACS analysis blots illustrate from left to right the effect of control TMZ, cRGD, and cRGD-BioShuttle-TMZ 
on the cell granular i t y   ( t o p   r o w )   a n d   o n   t h e   c e l l   s i z e   ( b o t t o m   r o w )   o f   M C F -7   c e l l s .   A s   s h o w n   i n   t h e   t o p   r o w   o f   t h e   f i g u r e ,   t h e  
granularity differs from the untreated control and increases from the left (via TMZ and cRGD) to the right column 
(cRGD-BioShuttle-T M Z ) ,   w h e r e a s   t h e  cell size remains unaltered (as shown in the bottom row). The highest granularity is 
shown in the MCF-7 cells treated with the cRGD-BioShuttle-T M Z   i n   a n   8 -fold reduced application dose (right column, top 
row). In comparison to the control (left column) the   M C F -7   c e l l s   s h o w   a n   i n c r e a s e d   a m o u n t   o f   a   f r a c t i o n   o f   g r a n u l a r i t y   c e l l s  
(R2).  
 
 
A   c o m p a r i s o n   o f   t h e   f l o w   c y t o m e t r y   d a t a   ( T a b l e  
1 )   t o   t h e   C L S M   d a t a   a s   s h o w n   i n   F i g u r e   3   r i g h t   c o l-
u m n   i s   u s e f u l .   I n   t h e   i m a g e   o f   t h e   2 4   h o u r s   t i me point 
after  application  with  cRGD-BioShuttle-dansyl  the 
MCF-7  cells  show  a  clear  perinuclear  endoplasmic 
reticular  located  blue  fluorescence  signal  which 
represents  an  increase  in  the  granularity  resulting 
f r o m   t h e   u n s t a i n e d   e n d o p l a s m i c   r e t i c u l u m   s u r-
roun d i n g   t h e   n u c l e u s .   A s   d e m o n s t r a t e d   i n   t h e   F i g u r e  
5 ,   s e c o n d   r o w ,   t h e   c e l l s   t r e a t e d   w i t h   1 0 0   µ M   T M Z  
s h o w   a n   i n c r e a s e d   a m o u n t   o f   g r a n u l a r   c e l l s   ( 2 0   % )  
compared to the untreated control with 4.5% granu-
l a r i t y .   I n   t h e   s a m p l e   o f   M C F -7 cells treated with the 
cRGD alone (100 µM), a cellular granularity of 33.2 % 
w a s   m e a s u r e d .   I t   i s   i m p o r t a n t   t o   n o t e   t h a t   t h e   M C F -7 
cells treated with cRGD-BioShuttle-T M Z   i n   a n   a t   l e a s t  
8-fold reduced application dose (12.5 µM) feature the 
highest  cell  response  with  a  cellular  granularity  of 
34.2%.  
Cellular sensitivity against cRGD, 
cRGD-BioShuttle-TMZ and TMZ alone - IC50 
values 
To  measure  the  chemotherapeutic  sensitivity 
against  the  investigated  components,  the  TMZ,  the 
cRGD, and the cRGD-BioShuttle-TMZ-conjugate were 
added  to  MCF-7  cells.  A g a i n ,   t h e   s u b s t a n c e s   w e r e  
dissolved  in  an  aqueous  dilution  series  in  culture 
m e d i u m   i n   a   c o n c e n t r a t i o n   f r o m   1 2 . 5   µ M   t o   1 0 0   µ M  
and applied over 72 hours. The data are presented in 
Table 1. With the flow cytometry analyses we showed 
the  high  sensitivity  of  MCF-7  against 
cRGD-BioShuttle-TMZ with an IC50 value of 12.5 µM, 
and  a  much  lesser  sensitivity  against  underivatized 
T M Z   w i t h   a n   I C 5 0   o f  1 0 0   µ M ) .   T h e   M C F -7   c e l l s   t r e a t e d  
with cRGD (12.5 up to 100 µM) were unimpressed. 
 
Table 1  Effect of the temozolomide (TMZ), cRGD, and 
cRGD-BioShuttle-TMZ on the MCF-7 breast cancer cell 
line. 
  TMZ  cRGD  cRGD-BioShuttle 
IC50 [µMol/L]  100  -  12.5 
pIC50  4  -  4.9 
 
 
Discussion 
As definitive treatments of metastases of breast 
cancer  remain  surgery,  radiation  therapy,  and  hor-
mone therapy in the case of metastatic progress. Cy-
t o g e n e t i c   c h a r a c t e r i s t i c s ,   l i k e   t h e   r a n g e   o f   t h e   c h r o-Int. J. Med. Sci. 2010, 7 
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mosome number between hypertriploidy and hypo-
tetraploidy, could answer the question of the recalci-
t r a n c e   o f   m e t a s t a t i c   b r e a s t   c a n c e r   c e l l s ,   e x e m p larily 
MCF-7 cells, against therapeutic interventions. But the 
t i m i n g   o f   t r e a t m e n t   f o r   a l l   s t a g e s   o f   t h e   d i s e a s e   r e-
mains controversial and new therapeutic approaches 
are needed [15,  16].   E n c o u r a g i n g   r e s u l t s   o f   t h e   c h e-
motherapeutic  T M Z   t r e a t m e n t   i n   b r a i n   t u m o r s   [17] 
remain u n e n d o r s e d   i n   t h e   t r e a t m e n t   o f   b r e a s t   c a n c e r  
cells.  
A  May  28th  2010 search in the NCBI database 
PubMed  with  “RGD”  “MCF-7” yields 26, and with 
“RGD” “HeLa” 89 hits. In its first 1995 publication the 
Huang  group  described  inhibiting  features  of 
RGD-containing  peptides  against  αvβ3  integrin  ex-
pressing cells [18] whereas the activity of αvβ5 integrin 
was  already  documented  from  the  Boulanger  and 
Nemerow groups in 1993 [19, 20].  
An explanation is that the integrin αvβ3 receptor 
is  expressed  at  low  levels  in  epithelial and mature 
end o t h e l i a l   c e l l s   b u t   i s   u p r e g u l a t e d   o n   t u m o r   c e l l s   a n d  
tumor  endothelial  cells   o f   v a r y i n g   t u m o r   t y p e s   i n-
cluding breast cancer, and therefore became consid-
ered as a prognostic factor in breast cancer [21]. It was 
also  documented  that  peptide  ligands  containing 
RGD  amino  acid  sequences   h a v e   a   h i g h  affinity for 
integrins and after labelling with radioisotopes, could 
be used for imaging αvβ3 receptor levels by PET or 
SPECT studies [22]. The use of RGD peptides ligated 
with imaging components for cell specific targeting as 
tumor-diagnosing  tool  is  broadly  documented  [23, 
24].   A l l   t h e s e   d o c u m e n t e d   r a d i o l i g a n d s   m a y   b e   v a l u-
able for monitoring antiangiogenic therapeutics.  The 
ligation  of  such  therapeutically  active  substances  to 
R G D   p e p t i d e s   c o u l d   o p e n   a   d o o r   f o r   s u c c e s s f u l  
treatment of hardly tractable tumors like metastases 
expressing  αvβ3  integrin.  In  comparison  with  the 
normal expression level of MCF-7 mammary cancer 
cells,  αvβ3  l o w   e x p r e s s i n g   H e L a   c e r v i x   c a n c e r   c e l l s  
were examined, which express the αvβ5 integrin  and 
correlate with low invasiveness.  
In flow cytometry, the increased relative amount 
o f   c e l l s   r e v e a l i n g   g r a n u l a r i t y   a n d   t h e   a c c e s s i o n   o f   t h e  
cell  fraction  featuring  a  clear  augmentation  of  the 
granularity both might result from increased numbers 
of  affected  mitochondria,  golgi  apparatus  or  endo-
plasmatic reticulum. This could be explained with  a 
p h a r m a c o l o g i c   e f f e c t   o f   t h e   c R G D ,   a s   w e l l   a s   o f   t h e  
TMZ  alone.  The  BioShuttle  construct  containing  the 
cRGD as targeting modul connected to the TMZ via 
the  Diels-Alder  Reaction  with  inverse  electron  de-
mand  [12]  targets  the  αvβ3  and  αvβ5integrin MCF-7 
cell  surface  proteins  as  shown  in  the  Figure  3.  Ac-
cording to CLSM-pictures of the MCF-7  cells (Figure 
3), an increased cytoplasmic coloring is indicative for 
a strongly increased amount of granularity  in  cells 
( R 2 )   i n   t h e   c y t o m etric results. It is important to note 
that no changes in cell size could be observed.  
The  results  of  the  present  study  demonstrate a 
close relationship of the reformulated drug to unan-
swered clinical questions as suitable solutions for the 
patients  (as  described in the introduction). Here we 
l i g a t e d   T M Z   t o   t h e   c R G D ,   a   p e p t i d e -based  compo-
nent, which accumulates at the cell’s membrane sur-
f a c e   h o l d i n g   a   t r e m e n d o u s   p o t e n t i a l   t o   o p t i m i z e  
therapy. Enhanced local concentrations of active sub-
s t a n c e s   l i k e   T M Z   a t   t he cells surface, a feasible site of 
pharmacological action, allow expecting lower appli-
cation  doses  with  concomitantly  decreased 
side-effects.  The  uptake  and  internalization  into  the 
c e l l s   c y t o p l a s m   i s   p r e s u m a b l y   d o c u m e n t e d   [25].  The 
criteria  to  determine  the  applicability  for  targeting 
including accessibility, specificity, safety and subcel-
lular  precision  are  documented  [26-30].   I n   o r d e r   t o  
fulfill a l l   t h e s e   b i o m e d i c a l   a s p e c t s ,   t h e   T M Z   d r u g   w a s  
bound  as  a  cargo  to  transporter  molecules 
(cRGD-BioShuttle-TMZ)  with  special  chemical 
methods [31].   T h e s e   c o u p l i n g   r e a c t i o n s   h o w e v e r ,   r e-
quired the reformulation of the active drug TMZ and 
c a n   l e a d   t o   n o v e l   p r o p e r t i e s   o f   t h e   T M Z .   C h e m o s e l e c-
tive  reaction-conditions  in  aqueous  solution  and  at 
r o o m   t e m p e r a t u r e   w e r e   o b t a i n e d   b y   c hemical ligation 
o f   f u n c t i o n a l   p e p t i d e s   v i a   t h e   D A R inv.  The  “click 
chemistry” based on the DARinv with “inverse elec-
tron demand” resulted in an impressive efficiency as 
illustrated in scheme 3/Figure S3 and is well docu-
mented [12]. This reaction enhanced the economics of 
the chemical reaction by the following parameters:  
increase of the reaction rate,  gentle reaction condi-
tions at room temperature, and  resulting in reaction 
kinetics with stoichiometric reaction partners without 
excess of the educts. The BioShuttle-mediated deliv-
ery and targeting platform can facilitate the transport 
t o   t a r g e t   c e l l s   [ 3 1 ,   3 2 ] .   D e s p i t e   t h e   f a c t   t h a t   t h e   I C 5 0  
value can vary, depending on factors like the cell line, 
the test protocol, and the investigator, this estimation 
gives useful and helpful information on the relative 
toxicity [32]. Regarding the difference in IC50 values 
between  the  TMZ  at  100  µmol/L  and 
cRGD-BioShuttle-T M Z   a t   1 2 . 5   µ m o l / L ,   i t   b e c o m e s  
obvious that the cRGD-BioShuttle-TMZ offers a high 
potential for treatment of patients and represents an 
attractive enhanced drug system for upcoming clini-
cal combined chemotherapeutic approaches [33, 34].  
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